Cardiac sympathetic denervation in Parkinson disease

Annals of Internal Medicine

Volumn 133, Issue 5, 2000, Pages

  Goldstein, D S ^a   Holmes, C ^a   Li, S T ^a   Bruce, S ^a   Metman, L V ^a   Cannon III, R O ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY SINUS; DENERVATION; DISEASE ASSOCIATION; DISEASE DURATION; HUMAN; NERVE ENDING; NORADRENALIN BLOOD LEVEL; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RADIOACTIVITY; SYMPATHETIC INNERVATION; VALSALVA MANEUVER;

EID: 0034609583     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-5-200009050-00009     Document Type: Article

References (36)

1. Prevalence of orthostatic hypotension in Parkinson's disease
2. Levodopa-induced postural hypotension. Treatment with fludrocortisone
3. Clinical and physiological characteristics of autonomic failure with Parkinson's disease
4. Autonomic dysfunction in Parkinson's disease, tested with a computerized method using a Finapres device
5. Autonomic dysfunction in pathologically confirmed multiple-system atrophy and idiopathic Parkinson's disease - A retrospective comparison
6. 123 meta-iodobenzylguanidine myocardial scintigraphy
7. 123I]iodobenzylguanidine in Parkinson's disease with autonomic failure
8. Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple-system atrophy, and progressive supranuclear palsy
9. 123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease
10. 123I]iodobenzylguanidine in neurological patients with autonomic failure
11. Total defect of metaiodobenzylguanidine (MIBG) imaging on heart in Parkinson's disease: Assessment of cardiac sympathetic denervation
12. 123I-MIBG uptake by the heart in Parkinson's disease: Assessment of cardiac sympathetic denervation and diagnostic value
13. Cardiac sympathetic denervation from the early stage of Parkinson's disease clinical and experimental studies with radiolabeled MIBG
14. 18F]fluorodopamine: Initial findings in humans
15. 6-Fluorocatecholamines as false adrenergic neurotransmitters
16. 18F] fluorodopamine positron emission tomographic scanning in the assessment of cardiac sympathoneural function - Studies in normal humans
17. Consensus statement on the diagnosis of multiple-system atrophy. American Autonomic Society and American Academy of Neurology
18. A clinicopathologic study of 100 cases of Parkinson's disease
19. 13N]ammonia
20. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection
21. Sympathetic cardioneuropathy in dysautonomias
22. In vivo measurement of neuronal uptake of norepinephrine in the human heart
23. Different relationships of spillover to release of norepinephrine in human heart, kidneys, and forearm
24. Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine
25. Plasma dihydroxyphenylalanine and total body and regional noradrenergic activity in humans
26. Neuronal source of plasma dihydroxyphenylalanine
27. 123I]MIBG separates Parkinson's disease from multiple-system atrophy
28. Age-related decline in the dopaminergic nigrostriatal system: The oxidative hypothesis and protective strategies
29. Oxidative stress: Free radical production in neural degeneration
30. An introduction to the free radical hypothesis in Parkinson's disease
31. Prevention of dopamine-induced cell death by thiol antioxidants: Possible implications for treatment of Parkinson's disease
32. The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease
33. Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: Studies comparing the cloned human noradrenaline and human dopamine transporter
34. Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals
35. Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: Mechanism of neuron death